✓ Independent editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Comparison

Compounded Tirzepatide vs Zepbound

Released: Last reviewed:

A side-by-side comparison of compounded tirzepatide (503A pharmacy pathway) and brand-name Zepbound® (Eli Lilly): cost, regulatory status, ingredient sourcing, and clinical implications in 2026.

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Side-by-side comparison

AttributeCompounded tirzepatideZepbound® (brand)
FDA approval statusNot FDA-approvedFDA-approved (chronic weight management, OSA)
Manufacturer503A compounding pharmacyEli Lilly
Active ingredientTirzepatide base (legitimate compounding); salt forms (acetate/sodium) subject to FDA warning lettersTirzepatide (Eli Lilly proprietary process)
Monthly cash price$139–$379/mo$1,059–$1,279/mo (cash MSRP)
Insurance coverageNo (cash-pay only)Many commercial plans, varies by formulary
HSA/FSA eligibleYes (with prescription)Yes
Drug shortage status (FDA Drug Shortage list)N/A — compounded supplyResolved (Oct 2024)
Form factorMulti-dose vial (draw with syringe)Pre-filled single-dose pen or vial
Quality assurance documentationUSP <71> / USP <85> / HPLC CoA from dispensing pharmacy (provider-dependent)FDA-inspected cGMP manufacturing

The 503A vs 503B distinction

503A pharmacies are state-licensed compounding pharmacies that prepare patient-specific medications under USP <797> sterile-compounding standards. They are not FDA-inspected for product release. 503B outsourcing facilities are FDA-registered and operate under cGMP standards (the same standard as commercial drug manufacturers). They can prepare batches in advance of patient-specific prescriptions. Read the full 503A vs 503B explainer →

What changed in April 2026

The FDA announced intent to restrict ingredients used in mass-marketed compounded GLP-1 medications and to crack down on misleading direct-to-consumer marketing. The FDA has previously issued warning letters specifically against compounded GLP-1 salt forms (tirzepatide acetate, tirzepatide sodium). Legitimate compounded tirzepatide must use tirzepatide base only. NexLife’s plan pages name three named state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA).

Who is each product right for?

Related guides